Clinical Trials Overview
BIG 1-14 / AURORA
Aiming to understand the molecular aberrations in metastatic breast cancer
BIG 2-13 / CL2-80881-001 (FINESSE)
A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer
BIG 4-11 (APHINITY): Herceptin® plus pertuzumab adjuvant study
A randomised, multi-centre, double-blind, phase III study of adjuvant trastuzumab plus pertuzumab or placebo in patients with HER2/ErbB2 positive primary breast cancer.
BIG 1-06 / EGF106903 / Neo-ALTTO BIG 01-06 (NEO-ALTTO): NEO-ADJUVANT LAPATINIB AND/OR TRASTUZUMAB
A randomised, multicentre open-label phase III study of neoadjuvant lapatinib, trastuzumab and their combination plus paclitaxel in women with HER2/ErbB2 positive primary breast cancer.
BIG 2-06 / N063D EGF 106708 / ALTTO BIG 02-06 / N063D (ALTTO) ADJUVANT LAPATINIB AND/ OR TRASTUZUMAB
A randomised, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer.
BIG 01-01 (HERA): Herceptin® adjuvant study
A randomized three-arm multi-centre comparison of 1 year and 2 years of Herceptin versus no Herceptin in women with HER2- positive primary breast cancer who have completed adjuvant chemotherapy.
BIG 02-98 (TAX 315): Taxotere® Study
An intergroup phase III trial to evaluate the activity of docetaxel, followed by CMF, in comparison to doxorubicin alone or in combination with cyclophosphamide, followed by CMF, in the adjuvant treatment of node-positive breast cancer patients.